author-photo

Rupert Sandbrink

University of Düsseldorf
Bayer HealthCare Pharmaceuticals
Bayer Corporation

106

Papers

8406

Citations

Citation Trend

Filter By

Papers (78) Sort By

Journal Conference Others

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

2016 Neurology
Show All
- Source
- Cite
- Save
Citations (80)
Long-term safety of interferon beta-1b (IFNB-1b) treatment in early multiple sclerosis ( MS): The 11-year follow-up of BENEFIT (BENEFIT-11)

2016 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)
Predicting conversion to clinically definite multiple sclerosis using machine learning on the basis of cerebral grey matter segmentations

2015 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)
Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept

2015 Retina-the Journal of Retinal and Vitreous Diseases
Show All
- Source
- Cite
- Save
Citations (14)
Scheduled versus Pro Re Nata Dosing in the VIEW Trials

2015 Ophthalmology
Show All
- Source
- Cite
- Save
Citations (32)
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT

2015 Neurology
Show All
- Source
- Cite
- Save
Citations (35)
Reply: To PMID 25068637.

2015 American Journal of Ophthalmology
Show All
- Source
- Cite
- Save
Citations (0)
Vitamin D as a Predictor of Functional Deficits in Multiple Sclerosis (P4.014)

2015 Neurology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)

2015 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)
MRI results in patients with CIS treated with interferon beta-1b: 11-year follow up in BENEFIT (BENEFIT 11)

2015 Multiple Sclerosis Journal
Show All
- Source
- Cite
- Save
Citations (0)